Biotech, Antibiotics, Enanta Pharmaceuticals

Enanta Pharmaceuticals Starts Clinical Trial of Antibiotic for Drug Resistant Bacteria

Luke Timmerman 9/15/08

Enanta Pharmaceuticals, a Watertown, MA-based developer of anti-infection drugs, said today it has started an early stage clinical of an oral antibiotic for drug-resistant bacteria. The drug, EDP-322, is being tested for hospital and community-acquired infections, including drug-resistant MRSA. In previous animal tests, the drug showed activity against MRSA strains that resist other potent antibiotics like vancomycin, Pfizer’s Zyvox, and Cubist Pharmaceuticals’ Cubicin.

Luke Timmerman is the National Biotechnology Editor for Xconomy. You can e-mail him at ltimmerman@xconomy.com, call 206-624-2374, or follow him on Twitter at http://twitter.com/ldtimmerman.